Evidence map›Paper›PMID 33403092›Full record

ArticleRare tumors2020

Angiosarcoma: A population-based cancer registry descriptive study of 45 consecutive cases diagnosed between 1979 and 2016.

Morgane Colas, Aurélie Gérazime, Dragos Popescu, Eve Puzenat, Loic Chaigneau, Anne Sophie Woronoff, Anne Sophie Dupond, Charlée Nardin, François Aubin

Abstract read
In one paragraph

Article in Rare tumors, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Bladder angiosarcoma: a systematic literature review and survival analysis.Proceedings (Baylor University. Medical Center) · 2025
    Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Morgane ColasSce de Dermatologie, Inserm 1098 RIGHT, Université de Franche Comté, Centre Hospitalier Universitaire, Besançon, France.
Aurélie GérazimeRegistre des Tumeurs du Doubs, EA3181, Université de Franche Comté, Centre Hospitalier Universitaire, Besançon, France.
Dragos PopescuSce de Dermatologie, Hôpital Nord Franche Comté, Trévenans, France.
Eve PuzenatSce de Dermatologie, Inserm 1098 RIGHT, Université de Franche Comté, Centre Hospitalier Universitaire, Besançon, France.
Loic ChaigneauService d'Oncologie Médicale, Centre Hospitalier Universitaire, Besançon, France.
Anne Sophie WoronoffRegistre des Tumeurs du Doubs, EA3181, Université de Franche Comté, Centre Hospitalier Universitaire, Besançon, France.
Anne Sophie DupondSce de Dermatologie, Hôpital Nord Franche Comté, Trévenans, France.
Charlée NardinSce de Dermatologie, Inserm 1098 RIGHT, Université de Franche Comté, Centre Hospitalier Universitaire, Besançon, France.
François AubinSce de Dermatologie, Inserm 1098 RIGHT, Université de Franche Comté, Centre Hospitalier Universitaire, Besançon, France.ORCID https://orcid.org/0000-0002-1421-4996

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Angiosarcoma (AS) is a rare aggressive sarcoma with differentiation toward blood or lymphatic endothelium. There are few epidemiological data available on AS. To address this limitation, we investigated the epidemiological and clinical features of angiosarcoma diagnosed in a French administrative area (the Doubs department) from 1979 to 2016. A retrospective cohort study was conducted using the Doubs cancer registry database. A total of 45 patients with invasive AS were diagnosed between 1979 and 2016 in the Doubs department. Among the 45 AS, 51% were either cutaneous AS (27%), including head and neck and extremities, or breast AS (24%) as compared to visceral AS (42%). Eleven patients had metastasis at diagnosis (26%). Age-standardized incidence rate was 0.15 per 100,000 persons-years (95%CI, 0.10-0.20) for the entire study period (1979-2016) and 0.26 (95%CI, 0.15-0.42) for the last decade (2007-2016). Crude survival at 1, 3, 5 years after diagnosis was 44%, 21%, and 12%, respectively. Our population-based study provides updated data on the incidence and overall survival of AS in a French population-based cancer registry.

Indexed as

angiosarcomaincidencesurvival

Identifiers

PMID33403092
PMCPMC7739202

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.